Continuous dosing of nikkomycin Z against systemic candidiasis, in vivo and in vitro correlates
Sign Up to like & getrecommendations! Published in 2023 at "Mycoses"
DOI: 10.1111/myc.13569
Abstract: Candidiasis is the most common cause of fungal sepsis, and new agents are of interest to ameliorate current deficiencies in therapy. Nikkomycin Z (NIKZ) is an inhibitor of chitin synthase, interfering with fungal cell wall… read more here.
Keywords: nikkomycin systemic; candidiasis vivo; candidiasis; systemic candidiasis ... See more keywords